Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. 

According to a release, the addition of Thrive’s early-stage cancer screening test, CancerSEEK, will help position Exact Sciences as a leading firm in blood-based, multi-cancer screening. The acquisition of Base Genomics will enhance Exact Sciences’ efforts in cancer diagnostics.

“The acquisition of Thrive is a giant leap toward ensuring blood-based, multi-cancer screening becomes a reality and eventually, the standard of care,” Exact Sciences CEO Kevin Conroy said in a statement. “We have long respected the Thrive team for their rigorous scientific approach.”

The biotech company also announced it will sell $869 million in new stocks in a direct offering to 10 institutional investors. The offering is expected to close on Thursday, Oct. 29.